Financing channel feed – Endpoints News

Financing channel feed

Can a Nektar rival make it on Nasdaq with a $100M IPO? Synthorx is giving it a shot

7 years ago

Can a 'rediscovered' drug from India make it big in US immunology space? Dan Bradbury and his team at Equillium want to prove yes

7 years ago

CStone braves the HKEX with late-stage plans brewing for newly beefed up I/O pipeline

7 years ago

Kymera raises $65M from global syndicate as it aims for the clinic with protein degradation tech

7 years ago

As Roivant’s unicorn valuation swells to $7B, Ramaswamy scoops up $200M to back a new burst of startups

7 years ago

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

7 years ago

Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA

7 years ago

Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics

7 years ago

Big dreams, big pay and a big IPO: Moderna lights up a pitch for a record $500M biotech IPO

7 years ago

Penn spinout preps for human studies of a new-model CAAR, aiming at a one-time cure for autoimmune diseases

7 years ago

InCarda grabs a $42M round to back PoC study for their inhaled cardio drug

7 years ago

Eyes on neuro breakthroughs, newcomer Biomatics adds biotech vets and $300M with second fund

7 years ago

Centrexion eyes $70M-$80M in IPO with big plans for PhIII non-opioid painkiller

7 years ago

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

7 years ago

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

7 years ago

Gene therapy developer Orchard prices IPO at $14 to raise $200M

7 years ago

Finally! Innovent hikes on Hong Kong debut amid cloudy market sentiments

7 years ago

WuXi dives into computational drug discovery, launches New York-based JV with Schrödinger

7 years ago

Arch Venture sets its sights on raising $600M for Fund X

7 years ago

Terns scores $80M in Series B financing led by Vivo, OrbiMed

7 years ago

Julian Adams manages to complete his $50M IPO at Gamida Cell — at a heavy cost

7 years ago

Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player

7 years ago

Novo-backed Galecto Biotech scores €79 million in Series C funding

7 years ago

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

7 years ago

First page Previous page 119 120 121122123 124 125 Next page Last page